Drug intelligence / Profile preview

TLM-002

Development stage: Unknown
Lead developer: Therillume

Overview

**TLM-002** is an investigational Therillume oncology program listed in the company pipeline for **glioblastoma multiforme** and **solid tumors**. Publicly available source material identifies it only by its development code and indicates a **Phase 1/2** development stage, with notes that it has completed multiple Phase 1 and 2 clinical trials in solid tumors. No reliable public details were found on the molecule's precise modality, molecular target, mechanism of action, formulation, or route of administration, so it is best treated as an undisclosed clinical-stage anticancer candidate from Therillume.

Beyond the preview

Go deeper on TLM-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLM-002.

Explore the full profile